Data are available via Dryad (doi: [10.5061/dryad.fbg79cnrg](https://doi.org/10.5061/dryad.fbg79cnrg)).

Introduction {#sec005}
============

CD4 cell count test has been used to determine when HIV infected patients should start antiretroviral therapy (ART) and to monitor ART \[[@pone.0230453.ref001]--[@pone.0230453.ref007]\]. CD4 cell count test has been key in predicting disease progression and death among people living with HIV, and it has been crucial for assessing eligibility of prophylaxis for opportunistic infections (OIs) \[[@pone.0230453.ref003], [@pone.0230453.ref004]\].

However, in 2013, World Health Organization (WHO) recommended the use of HIV Viral load (VL) for monitoring ART over CD4 cell counts as VL accurately detects virological failure before immunological or clinical deterioration \[[@pone.0230453.ref008]\]. As such, nearly 95% of low and middle income countries (LMIC) have implemented policies for scale up of VL testing \[[@pone.0230453.ref009]\].

In-spite of continuous improvements in ART coverage and monitoring, the decline in HIV/AIDS-related mortality is stalling. In 2018 nearly 770, 000 people died from AIDS related-diseases, a mere 30,000 less than the previous year \[[@pone.0230453.ref010]\]. Many HIV programs in LMICs continue to report significant proportions of treatment-naive and treatment-experienced patients presenting to care with advanced HIV disease (AHD). AHD is defined as an adult, adolescent, or child greater than 5 years old with a CD4 cell count \<200 cells/mm^3^ or a WHO clinical stage 3 and 4 event as well as all children less than 5 years \[[@pone.0230453.ref002]\]. Patients presenting with AHD are at high risk of death, even after starting ART. CD4 cell count testing is important to aid in identifying ambulatory and asymptomatic patients eligible for further AHD screening and a result of CD4 cell count less than 200cells/mm^3^ triggers screening for urinary mycobacterial tuberculosis lipoarabinomannan antigen (TB LAM) and cryptococcal antigen (CrAg) \[[@pone.0230453.ref002]\] using TB LAM and CrAg POC lateral flow assays (LFA). This package of care for AHD should be offered at hospitals, decentralized primary health care clinics including at peripheral sites and even through mobile outreach \[[@pone.0230453.ref002]\].

Although there are at least three commercially available point-of-care (POC) or near-POC CD4 assays in the market (Abbott Pima (Abbott, Chicago, IL, USA), BD FACSPresto (BD Biosciences, San Jose, CA, USA) and CyFlow miniPOC (Sysmex Partec, Goertlitz, Germany)), these rely on instrument analysers for CD4 measurement \[[@pone.0230453.ref011]\]. They require a considerable initial capital investment on instrumentation, usually more than USD \$5,000, as well as a continuous service and maintenance for instrument repairs. It has also been previously reported that instrument-based POC CD4 technologies are prone to breakdowns and can generate a considerable amount of invalid test results \[[@pone.0230453.ref012]\] therefore adding to the test cost. Furthermore, with focus on VL scale-up to monitor ART, and stagnating donor health funding \[[@pone.0230453.ref013]\], sustainability of instrument-based CD4 technologies is uncertain. As such, there is a need for instrument-free and affordable POC CD4 technologies amenable for decentralization to expedite implementation of the AHD package which has a mortality benefit.

Developed by the Burnet Institute, the Omega VISITECT CD4 Advanced Disease Lateral Flow Assay (Visitect CD4 LFA) (Omega Diagnostics, Scotland, UK), is a disposable POC test that offers an estimation of the CD4 protein on the surface of CD4+ T cells, providing a semi-quantitative results at a threshold of 200cells/mm^3^ \[[@pone.0230453.ref014]\]. This study sought to evaluate the diagnostic accuracy and feasibility-of-use for this first-ever instrument free POC CD4 test, which provides a visually interpreted result, of above or below 200 CD4 cells/mm^3^, after 40 minutes.

Methods {#sec006}
=======

Study design and setting {#sec007}
------------------------

This was a prospective two phased diagnostic accuracy and feasibility-of-use evaluation study, conducted in Médecins Sans Frontiéres (MSF) supported health facilities of; Nsanje district hospital (NDH) (Malawi), Gutu mission hospital (GMH) (Zimbabwe) and Centre hopitalier de Kabinda (CHK) Democratic Republic of Congo (DRC). CHK is a tertiary HIV referral health facility whilst NDH and GMH are rural district hospitals. Phase 1 of the study was a diagnostic accuracy evaluation of the Visitect CD4 LFA compared to the BD FACSCount assay (BD Biosciences, San Jose, CA, USA) within the study site laboratories while Phase 2 was carried out at the patient site, to assess the feasibility of use of the index test.

Study population {#sec008}
----------------

All HIV positive adult (18 to 64years) patients eligible for a CD4 test for any reason and providing a written informed consent, were eligible.

Sample size {#sec009}
-----------

Sample size estimation for Phase 1 was guided by an expected 25% prevalence of patients with CD4\<200cells/mm^3^ from the three study sites and expected point estimates of sensitivity and specificity of 80% and 75% respectively in the index test. A minimum of 660 patients were considered to achieve margins of sampling error of approximately 2% for point estimates with more than 90% power. For phase 2 study, sample size estimation was established on a convenient sampling of a minimum of 425 patients, based on pragmatic bi-monthly CD4 cell testing volumes in the study sites.

Sample collection {#sec010}
-----------------

In Phase 1, venous EDTA blood sample (3ml) was collected from each consenting patient for routine CD4 testing at the laboratory (on the BD FACScount platform) and the excess sample was also tested for CD4 cell count in the index Visitect CD4 LFA ([Fig 1](#pone.0230453.g001){ref-type="fig"} flow chart). During Phase 2, all prospective eligible patients who provided written informed consent, had routine venous EDTA blood sample collected together with a finger-prick (FP) sample. The FP sample was for simultaneous POC testing, on the Visitect CD4 LFA and on the PIMA CD4 POC, whereas the EDTA sample was sent for testing at the laboratory.

![Study sample collection and testing flow.\
Key: \*IPD-in-patient department, ¥OPD-out patient department.](pone.0230453.g001){#pone.0230453.g001}

Testing procedures {#sec011}
------------------

BD FACSCount CD4 cell count: EDTA whole blood samples were transported at room temperature to the facility laboratory within 2 hours of collection. The samples were processed in the BD FACSCount CD4 machine (Becton Dickinson, San Jose, California, USA) according to the manufacturers' instructions, and laboratory standard operating procedures (SOPs) \[[@pone.0230453.ref015]\]. For PIMA CD4 POC testing; the finger prick (FP) blood sample was added to the Pima CD4 reagent cartridge and the cartridge was inserted into the Abbott PIMA CD4 device (*formerly Alere*) and processed following manufacture instructions and laboratory SOPs \[[@pone.0230453.ref016]\]. Commercial controls and proficiency testing (PT) results were used to assure quality in CD4 testing services.

The Visitect CD4 LFA test kit contains a disposable test device, one buffer bottle, a 30μL micropipette, a safety lancet and an alcohol swab. User training was provided by the Omega team. The Visitect CD4 LFA testing was conducted following the manufacturer's instructions for use (IFU); briefly, FP blood was obtained using the safety lancet; and the disposable pipette was used to collect 30μL of the FP sample. The blood sample was added into the Well A and incubated for 3 minutes, during which red blood cells and monocytes are retained in the blood sample collection pad ([S1 Appendix](#pone.0230453.s001){ref-type="supplementary-material"}). Thereafter, one drop of buffer is added into Well A and incubated for 17 minutes, during which other white blood cells (including CD4+ T-cells) migrate to a reaction area where cell lysis occurs resulting in the release of the full length CD4 for capture in the test strip. After 17 minutes, 3 drops of the buffer are then added into Well B so as to release the colloidal gold labeled monoclonal antibody conjugate that forms the reference line and the control line. The test results can be read after 20 minutes. Test results are visually interpreted by comparing the color intensity of the test line (T) with that of the reference line (200); if the test line (T) is darker than reference line (200), the patient has CD4 cell count \>200cells/mm^3^ and if the T line is fainter or similar intensity to the 200 reference line, then the patient has CD4cell count \<200cells/mm^3^ ([S2 Appendix](#pone.0230453.s002){ref-type="supplementary-material"}). Venous EDTA blood can also be used with the test. The Visitect CD4 LFA test kit can be stored within temperature ranges of 2--30°C.

In the study, Visitect CD4 LFA results were read by two independent operators who were blinded to each other's result and to the BD FACScount absolute CD4 result.

During Phase 1, the study also assessed the precision of Visitect CD4 LFA test (repeatability of CD4 measurements from the same sample in same environmental conditions) by the same individual. Visitect CD4 LFA test result reproducibility was assessed through varying the incubation times to beyond manufacture IFU by different laboratory technicians. The study also investigated Visitect CD4 LFA test result stability; where device testing results were first read following the manufacturer IFU, and later re-read by two blinded and independent readers daily for one week, to assess stability of results.

A self-completed questionnaire to explore Visitect CD4 LFA usability was administered to all testers who had conducted a minimum of 10 tests.

Data management and ethical approval {#sec012}
------------------------------------

Data was entered into a password-protected Microsoft Access data base and only accessible to authorised staff involved in data management. Diagnostic performance was explored using sensitivity, specificity and precision. Data was analysed in Stata-14. Usability responses from the testers' questionnaires were scored and described as percentages. This study was approved by the University of Malawi-College of Medicine Research and Ethics Committee (1891), University of Kinshasa Ethics Review Board (078/2018), Medical Research Council of Zimbabwe (MRCZ/A/2430) and by the MSF Ethical Review Board (1747).

Results {#sec013}
=======

Characteristics of study participants in Phase 1 {#sec014}
------------------------------------------------

A total of 708 patients were enrolled into the diagnostic accuracy study (Phase 1) and 63.6% were from DRC. Overall median age was 42 years \[IQR: 34--50\] and 67.2% of the participants were female. Median CD4 cell count was 297 cells/mm^3^ \[IQR: 170--499\] and 31.2% had CD4\<200cells/mm^3^, [Table 1](#pone.0230453.t001){ref-type="table"}.

10.1371/journal.pone.0230453.t001

###### Characteristics of study participants in Phase 1.

![](pone.0230453.t001){#pone.0230453.t001g}

  Variable                                                                Proportion n (%)
  ----------------------------------------------------------------------- ------------------
  **Total**                                                               708
  **Gender**                                                              
   Male                                                                   227 (32.1)
   Female                                                                 476 (67.2)
   Unknown                                                                5 (0.7)
  **Median age (years) \[IQR\]**                                          42 \[34--50\]
  **Median CD4 (cells/mm**^**3**^**)**                                    297 \[170--499\]
  **Reason for CD4 testing**                                              
   Advanced HIV disease screening                                         272 (38.4)
   ART initiation                                                         267 (37.7)
   ART monitoring                                                         98 (13.8)
   Other                                                                  71 (10.0)
  **Participant morbid conditions**[§](#t001fn002){ref-type="table-fn"}   
   TB                                                                     178 (25.1)
   Malaria                                                                26 (3.7)
   Cryptococcal meningitis                                                14 (2.0)
   Toxoplama ghondii                                                      7 (1.0)
   Severe bacterial sepsis                                                11 (1.6)
   Other                                                                  152 (21.5)
   Missing                                                                320 (45.1)

Key:

**§** Majority of patients were presenting with multiple morbidities. Also, as data was collected prospectively, a significant number of patients had 'unknown diagnosis' upon time of initial consultation (i.e time of study patient data collection).

Diagnostic performance of the Visitect CD4 LFA test compared to the BD FACScount {#sec015}
--------------------------------------------------------------------------------

Compared to BD FACScount assay, the sensitivity of the Visitect CD4 LFA (at the 200cells/mm^3^ threshold) using venous blood samples in the laboratory was 95.0% \[95% CI: 91.3--97.5\] and specificity was 81.9% \[95% CI: 78.2--85.2%\].

The median CD4 cell count of the 88/708 ([Table 2](#pone.0230453.t002){ref-type="table"}) misclassified by Visitect CD4 LFA as CD4\<200cells/mm^3^ was 252cells/mm^3^ \[IQR: 222--306\], whereas for the 11/708 misclassified as CD4\>200cells/mm^3^, their median CD4 cell count was 178cells/mm^3^ \[IQR: 134--185\].

10.1371/journal.pone.0230453.t002

###### Contingency table of Visitect CD4 LFA test results with BD FACScount.

![](pone.0230453.t002){#pone.0230453.t002g}

                     Visitect CD4 LFA         
  ------------------ ------------------ ----- -----
  **BD FACScount**                            
  CD4\<200           210                11    221
  CD4\>200           88                 399   487
  Total              298                410   708

Diagnostic performance of Visitect CD4 LFA at different CD4 cut-offs of the reference test {#sec016}
------------------------------------------------------------------------------------------

In restricting the analysis to samples with CD4\<100cells/mm^3^ cut-off in the reference test, the sensitivity of the Visitect CD4 LFA (at its standard 200cells/mm^3^ threshold) in detecting samples with CD4\<100cells/mm^3^ was 98.1% \[IQR: 93.5--99.8\] and specificity was 68.0% \[IQR: 64.1--71.7\]. [Table 3](#pone.0230453.t003){ref-type="table"} below, shows further diagnostic performance of the Visitect CD4 LFA to different CD4 cut-offs ranges of the reference test.

10.1371/journal.pone.0230453.t003

###### Diagnostic performance of Visitect CD4 LFA at different CD4 cut-offs of the reference test.

![](pone.0230453.t003){#pone.0230453.t003g}

  CD4 range (n; %)        Sensitivity (%), 95% CI   Specificity (%), 95% CI
  ----------------------- ------------------------- -------------------------
  \<100 (108; 15.3%)      98.1 \[93.5--99.8\]       68.0 \[64.1--71.7\]
  100--200 (113; 16.0%)   92.0 \[85.4--96.3\]       67.4 \[63.5--71.2\]
  \<200 (221; 31.2%)      95.0 \[91.3--97.5\]       81.9 \[78.2--85.2\]
  \<350 (417; 58.9%)      68.8 \[64.1--76.7\]       96.2 \[93.3--98.1\]

### Visitect CD4 LFA precision testing data (intra-assay) {#sec017}

Of the 12 excess EDTA samples (6 with CD4\<200 and 6 with CD4\>200cells/mm^3^ on the reference test), tested 3 times each, all gave results concordant with the reference test (100% precision).

### Visitect CD4 LFA reproducibility data from varying incubation times {#sec018}

Of 6 EDTA samples tested 5 times each (three with true CD4\>200 and three with \<200) while varying only the first incubation times (to 1min, 2 mins, 5 mins, 8 mins and 10 mins); there was incidence of result transition among those with initial CD4\>200 (5/30; 16.7%) to a result of CD4\<200, if the first incubation times were less-than 3mins. However, when the first incubation time was greater than 3mins, only one test transitioned to CD4\>200 (1/30; 3.3%) from true CD4\<200.

Of another 6 EDTA samples tested 5 times each while varying only the second incubation times (to 5 mins, 10 mins, 20 mins, 25 mins and 30 mins); there was no overall result transition observed as test results remained similar. Similarly, there was no overall result transition observed while varying only the third incubation times (10 mins, 15 mins, 25 mins, 30 mins and 35 mins), as test results remained similar.

### Visitect CD4 LFA result re-reading stability data {#sec019}

After one-week of ambient laboratory temperature (24--28°C) incubation of the Visitect CD4 LFA test result cassettes, with double blinded daily result re-reading, there was no observed incidence of Visitect CD4 LFA result transition between states. Of the total 18 results (12 true CD4 greater than 200 cells/mm^3^ and 6 true CD4 less than 200 cells/mm^3^); all maintained their initial testing results. The control and reference lines remained fairly stable throughout the re-reading period.

Visitect CD4 LFA usability at point-of-care (Phase 2) {#sec020}
-----------------------------------------------------

A total of 433 patients were enrolled into the feasibility evaluation of the study (Phase 2) and 343 (79.2%) were from DRC. Overall median age was 41 years \[IQR: 33--48\], 67% were female and median CD4 cell count was 242 cells/mm^3^ \[IQR: 103--436\]. Compared to BD FACScount assay, the sensitivity of the Visitect CD4 LFA (at the 200cells/ul threshold) using finger prick blood samples was 98.3% \[95% CI: 95.0--99.6\], specificity was 77.2% \[95% CI: 71.6--82.2%\]. The kappa statistical agreement between PIMA CD4 and Visitect CD4 LFA testing was 85.2%.

Out of 26 health care workers (HCW) who performed the Visitect CD4 LFA testing (8 nurses, 9 doctors, 9 lab techs), all had conducted more than 10 un-assisted tests and overall testing success test rate was 97.2% (1141/1173) with only 32 invalids observed due to operator failures (buffer added into incorrect Well, reading test result after 20mins and adding sample into incorrect Well). In the hands of the testers (both laboratory and non-laboratory trained testers), the median hands-on time for a single Visitect CD4 LFA test was 3mins \[2-6mins\] and the overall average testing time (from commencement of FP sample collection to result interpretation) was 45 minutes. Ninety percent reported that it was easy to comprehend the instructions after training, and after conducting a median of 4 tests \[IQR: 1--6\], testers felt confident in independently conducting the Visitect CD4 LFA.

Visitect CD4 LFA test result interpretability was one of the highest risk stage for user-errors; where 10 (38.5%) were not confident to interpret test results by comparing it to the reference threshold 200 line only, but they needed the pictorial IFU result picture to help correctly distinguish test lines, especially for test lines (T) very close in intensity to the reference line. Due to the precise incubation times and the multi procedural steps required for performing the test, a few health workers (27%) were not confident to manage the Visitect CD4 LFA testing whilst multi-tasking in their other work roles, however, this was less-felt so by the laboratory based staff. On overall perception, 70% participants would use the test kit again, and 85% recommended its use to primary and peripheral health care levels.

Discussion {#sec021}
==========

The Visitect CD4 LFA achieved a high level result agreement with reference testing instruments when used by laboratory trained HCW on venous blood (sensitivity of 95.0% and specificity of 81.9%) and by clinicians on FP samples at POC (sensitivity 98.3% and specificity of 77.2%). The slight reduction in specificity when used by clinicians is possibly due to the use of FP samples at POC, as opposed to venous blood samples and testers generally considered FP sample collection to be slightly challenging, [Fig 2](#pone.0230453.g002){ref-type="fig"}. Studies have also found that FP sampling requires adequate training so as to minimize excessive finger squeezing during sample collection, as this can lessen the possible dilution effect of tissue fluid \[[@pone.0230453.ref017]--[@pone.0230453.ref019]\]. Nonetheless, with adequate training and regular FP sample collection, HCWs could achieve similar results with venous blood sample testing.

![Perception of the risk of operator-errors in the Visitect CD4 LFA testing workflow among testers.](pone.0230453.g002){#pone.0230453.g002}

Data from this study showed that Visitect CD4 LFA has a trend of better sensitivity at very low (\<100cells/mm^3^) and better specificity at very high CD4 cell counts (\>350cells/mm^3^), [Table 3](#pone.0230453.t003){ref-type="table"}. This indicates the index test's reliability in detecting those at greatest risk of AHD (in need for CrAg and urine TB LAM LFA tests) and reliability in excluding those with higher CD4 categories (avoidance of unnecessary further tests for those at least risk). Studies have shown that majority of CM manifests at very low CD4 cell counts 100--150 cells/mm^3^ \[[@pone.0230453.ref020]\] and utility of urine TB LAM is best at CD4\<200 \[[@pone.0230453.ref002]\], as such, Visitect CD4 LFA could expedite utilization of these minimal AHD diagnostic tools.

There was a significant proportion of patients who were misclassified by Visitect CD4 LFA (in Phase 1 and 2 of the study) as having CD4 less than 200 cells/mm^3^ (147/1141; 12.9%) and this could trigger potential 'over-use' of CrAg and urine TB LAM tests. These misclassified patients still had a relatively low median CD4cell count (259 cells/mm^3^ \[IQR: 224--315\]). In ambulatory settings where median CD4 counts may be high, this lack of specificity will result in a relatively low positive predictive value. Nonetheless, patients with AHD have a very high mortality risk \[[@pone.0230453.ref020]\] and use of a simple and affordable screening test is justifiable even if it can result in few wasted investigations. On the other hand, only 14/1141 patients with CD4 cell counts less than 200cells/mm^3^ were misclassified as not having AHD and they could have missed further management.

Varying the test incubation times produced a different mix of results and testers must adhere to all the three IFU stipulated precise sequential incubation times of 3 then 17 and 20 minutes. If the first incubation time is less than the manufacture stipulated 3 minutes, the test line (T) is likely to be faint (potentially over-diagnosing AHD), however, if the first incubation is beyond 3 minutes, possibly strong test lines (T) can be formed (potentially under-diagnosing AHD).

Even though delayed Visitect CD4 LFA result re-reading did not produce any result transitions, we do not advise such, either for monitoring or validating another testers' result interpretation.

Implementation of the Visitect CD4 LFA must be accompanied by clear examples of possible test result interpretations in the IFU as testers will struggle to interpret test (T) lines, especially test results line with intensity closer to the reference threshold. Additional support, such as provision of instructional video, is recommended. With adequate training of HCW and with many testing opportunities or requests, the test could be easy to implement in practice.

Visitect CD4 LFA should be used as a rule-out test and it can be used together with WHO symptom screen especially as it can identify asymptomatic AHD cases. Studies have shown that clinical screening alone could miss up-to 50% of AHD cases in ambulatory settings \[[@pone.0230453.ref020]\].

Where access to CD4 testing instruments is lacking, particularly at primary care, use of Visitect CD4 LFA may-be valuable to ensure early identification of those at risk of AHD and mortality. Such a test at peripheral clinics, could minimize referral of CD4 tests and referral of un-complicated patient cases to higher-level clinical sites. Furthermore, mobile clinics, key populations (KP) and even community ART clubs may also benefit from use of Visitect CD4 LFA.

The burden of carrying out this and other essential simple tests \[[@pone.0230453.ref021], [@pone.0230453.ref022]\] may require investment in a dedicated lay cadre to ensure that the precise multi-stage manipulation of this test is accurately adhered to, plus reflex testing for samples with CD4 cell count less than 200cells/mm^3^. This cadre could also coordinate all other POC quality assurance (QA) in the PHC facility. The much anticipated FujiFilm TB urine LAM POC test (FujiFilm, Tokyo, Japan) also has a multi-step testing procedure which requires precision and concentration during the incubation times \[[@pone.0230453.ref023]\]; as such, a specific lay cadre could streamline these and other tests for reliable and prompt accurate results. National programs already have different lay cadres who could be responsible and accountable for AHD at PHCs. For example, in Malawi, Health Diagnostic Assistants (HDAs), have solely been utilized by partners (MSF, Partners-In-Hope among others) for other activities including AHD POC testing at PHCs without laboratories. Other countries have lay counselors, nurse assistants, health facility navigators, community health workers, phlebotomists, all of whom can potentially take up this role.

It would be valuable if the Visitect CD4 LFA manufacturer considers revising the current test cassette and make an inscription of the blood and of a buffer drop next to Well A, whereas in Well B three buffer drops must be inscribed. This could minimize mistakes of testers adding blood samples or buffer drops to incorrect wells as it was noticed in the present study. We recommend pilot implementation of AHD package of Visitect CD4 LFA, together with CrAg and urine TB LAM, to explore their feasibility at peripheral settings including assessing patient's acceptability of such POC tests.

Strengths of this study include multi-country implementation and large sample sizes especially within cohort of patients with high immunosuppression (intended beneficiaries of such a test). The main limitation of this study is that it was only conducted at a tertiary and secondary health facility and not in peripheral PHCs.

Conclusion and recommendation {#sec022}
=============================

Visitect CD4 LFA is an assuring test for decentralized CD4 testing in resource-limited settings, especially within PHCs with no access to CD4 testing instruments and it can trigger prompt management of patients with AHD. Lay health cadre roles should be reviewed with a consideration to assign Visitect CD4 LFA POC testing, including responsibility for QA of other POC tests in PHCs, to this cadre.

Supporting information {#sec023}
======================

###### Visitect CD4 LFA testing procedure using finger prick blood sample.

(TIF)

###### 

Click here for additional data file.

###### Visitect CD4 LFA result interpretation.

(TIF)

###### 

Click here for additional data file.
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5\) The authors shared the Kappa statistic of the Visitect CD4 LFA compared to the Pima CD4, but not the specificity or sensitivity. I recommend sharing the sensitivity and specificity with the Pima CD4 as the reference assay, or an explanation of why the authors chose to use venous blood tested on the BD FACScount as the reference assay for FP samples tested on the Visitect CD4 LFA.

Reviewer \#2: A few suggestions to strengthen the manuscript:

1\. The authors use sensitivity and specificity to describe the correlation between the different methods at the threshold of 200, which introduces some confusion as compared with test evaluations that compare positives and negatives as is done in most method comparisons. It might be more clear to describe the relationship as a correlation or concordance of methods at \>200 or \<200. Alternatively, it could be stated as the sensitivity or accuracy to detect \<200 and the sensitivity or accuracy to detect \>200.

2.Precision studies: Were any samples used that produced an equal result intensity with the 200 line? That is, precision studies should include a sample near the cutoff where changes could be realized. The nature of the samples used is not described in the Methods Section.

3\. Reproducibility study: What is described is not a reproducibility study; it describes an experiment where incubation times are varied and the effect on results is observed. The authors should consider to remove this because it is small in scope, not relevant for the user because they are supposed to follow instructions, and it might give the impression that incubation times can be varied without having an effect on test results. If it were to be included, then perhaps there should be other investigations also (e.g., varying the number of drops of buffer, using partial volumes of sample, etc.) to be more complete. A true reproducibility study shows how the test performs with multiple testing of the same samples over hours, days, or longer, and with varying conditions (different users, different temperatures on days, etc.).

4\. Line 176 is a partial sentence.

5\. Line 253 - the ambient temperature should be stated (in some resource limited countries it could be 35C). Stability could also mean how the test performs after storage at different temperatures over time. Therefore, it should refer to \"stability of the observed results\".

6\. In the early years of 2000, there was a method called TRAxCD4 (T Cell Dxs/Innogenetics) that was an ELISA based method that measured soluble CD4 protein in a sandwich configuration (similar to the principle in this LFA). The authors should review the literature and include any references in their manuscript.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Niel Constantine, Ph.D.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

13 Jan 2020

We would like to thank the reviewers for their time and concise inputs.

This study was initially submitted to PLOS-One with results from two study sites (Malawi and DRC); however, the study in Zimbabwe has also been finished recently and we have herein added the results from Zimbabwe for 118 patients tested in Phase 1. We also added the co-investigator details from Zimbabwe and also added the Ethical Approvals obtained from the Zimbabwe Medical Research Council.

Responses to reviewer comments

Reviewer \#1:

Reviewer comment 1: I suggest including your reference method in the abstract.

Author response: line 66 and 67 of the abstract do mention the reference test method used in the study (i.e BD FACSCount assay for CD4 testing)

Reviewer comment 2: On line 176 of the methods section, the following sentence was cut-off "The Visitect CD4 LFA test kit can be stored"

Author response: We have corrected the sentence and it now reads; "The Visitect CD4 LFA test kit can be stored within temperature ranges of 2 - 30oC" (line 195).

Reviewer comment 3: When assessing the performance of Visitect CD4 LFA at different reference test cut-offs, I recommend including the number of samples compared at each cut-off.

Author response: We have added the number and percentage of samples for each of the cut-off ranges (line 248, table 3)

Reviewer comment 4: On line 223, the authors state "In restricting the analysis to samples with CD4 \< 100 cellsmm3 cut-off in the reference test, the sensitivity of the Visitect CD4 LFA was 98% \[IQR: 93.1 -- 99.8\] and specificity was 66.6% \[IQR: 62.2 -- 70.8\]." If the analysis was truly restricted to reference values \< 100 cells/mm3 then there would be no false-positives from the test assay because there would be no reference values \> 200 cells/ml. Was this analysis instead performed by changing the cut-off of the reference assay? I recommend a better explanation of this analysis here or in the methods section.

Author response:

We have modified the sentence to reflect that the sensitivity/specificity of Visitect CD4 LFA at the different cut-offs is purely based on the reference assay cut-offs, whilst the Visitect CD4 LFA remains with its standard threshold of 200cells/mm3. Line 242-244. Furthermore, we avoid mentioning the words 'false positive/false negative' during the interpretation of the results of this restriction analysis.

Reviewer comment 5: The authors shared the Kappa statistic of the Visitect CD4 LFA compared to the Pima CD4, but not the specificity or sensitivity. I recommend sharing the sensitivity and specificity with the Pima CD4 as the reference assay, or an explanation of why the authors chose to use venous blood tested on the BD FACScount as the reference assay for FP samples tested on the Visitect CD4 LFA.

Author response: we used the Kappa statistic to compare diagnostic performance of Visitect CD4 LFA to PIMA (and not the sensitivity/specificity) because PIMA is not a reference standard method for CD4 cell count testing, as such Kappa statistic is the most correct/recommended way to assess the agreement between two methods (where there is no reference/gold standard) as both are considered imperfect tests.

Reviewer \#2:

Reviewer comment 1: The authors use sensitivity and specificity to describe the correlation between the different methods at the threshold of 200, which introduces some confusion as compared with test evaluations that compare positives and negatives as is done in most method comparisons. It might be more clear to describe the relationship as a correlation or concordance of methods at \>200 or \<200. Alternatively, it could be stated as the sensitivity or accuracy to detect \<200 and the sensitivity or accuracy to detect \>200.

Author response: Yes, we understand the potential 'confusion' that could arise with interpreting results for such a binary-test which doesn't necessarily provide the traditional 'positive' or 'negative' results. The consequence is that Visitect CD4 LFA results that are \<200 can loosely be called 'positive' whilst those \>200 can be said to be 'negative'.

In our study and in data analysis packages, as long as diagnostic result outcomes are dichotomous/binary, they are automatically labeled as 'normal' and 'abnormal', which enables determination of sensitivity/specificity to a reference standard method. This is regardless of whether the result is positive/negative or is \<200/\>200. Nonetheless, in the manuscript, we do emphasize (in multiple occasions) that the calculated outcomes of performance are sensitivity/specificity to detect CD4 cell counts at the 200cells/mm3 threshold (meaning either \>200 or less than 200), line 230-232.

Reviewer comment 2: Precision studies: Were any samples used that produced an equal result intensity with the 200 line? That is, precision studies should include a sample near the cutoff where changes could be realized. The nature of the samples used is not described in the Methods Section.

Author response: Line 199-201 in Methodology section does partly mention the strategy for assessing the precision of the index test. In line 250-253 (results section), we do mention the outcomes of precision assessment, and the fact that we used 12 samples and 2 had CD4 cell counts close to the 200cells/mm3 threshold. Nonetheless, we certainly do acknowledge the need to describe the samples used for precision; however, since we used a range of samples (in terms of CD4 cell counts) we could not manage to describe all the sample types used within the methodology/results section.

Reviewer comment 3: Reproducibility study: What is described is not a reproducibility study; it describes an experiment where incubation times are varied and the effect on results is observed. The authors should consider to remove this because it is small in scope, not relevant for the user because they are supposed to follow instructions, and it might give the impression that incubation times can be varied without having an effect on test results. If it were to be included, then perhaps there should be other investigations also (e.g., varying the number of drops of buffer, using partial volumes of sample, etc.) to be more complete. A true reproducibility study shows how the test performs with multiple testing of the same samples over hours, days, or longer, and with varying conditions (different users, different temperatures on days, etc.).

Author response: We acknowledge that our reproducibility part of the study is limited in scope and the idea behind it was purely to explore the effect of varying the incubation times only; as we pragmatically know that this will be one of the biggest independent factors to affect test results in different real user settings. Practically, we know health-care workers sometimes do not follow the instructions for use (IFU) for many POC diagnostics and with this multi-step test; we sought to show the potential consequences of not following the instructions. We do acknowledge that our findings may be taken to mean that the incubation times can be changed, but we specifically sought to provide a clue on this question that these incubation times are un-forgiving and testers must adhere to manufacture times. To simplify the text in the manuscript, we have removed part of the reproducibility data (Table 4) to ensure limited information remains; and the Discussion section (line 339-347) provide a clear emphasis on following manufacture incubation times.

Reviewer comment 4: Line 176 is a partial sentence.

Author response: We have corrected the sentence and it now reads; "The Visitect CD4 LFA test kit can be stored within temperature ranges of 2 - 30oC" (line 195).

Reviewer comment 5: Line 253 - the ambient temperature should be stated (in some resource limited countries it could be 35C). Stability could also mean how the test performs after storage at different temperatures over time. Therefore, it should refer to \"stability of the observed results\".

Author response: we have modified this and clarified that the ambient laboratory temperature range was 24--28oC. Line 269 Furthermore, we have added the word 'result re-reading' in the subtitle (line 268) to emphasize that the stability results are just from re-reading the stored test cassettes only.

Reviewer comment 6: In the early years of 2000, there was a method called TRAxCD4 (T Cell Dxs/Innogenetics) that was an ELISA based method that measured soluble CD4 protein in a sandwich configuration (similar to the principle in this LFA). The authors should review the literature and include any references in their manuscript.

Author response: We have done a literature review of this TRAXCD4 technology and many others during the early 2000 and we have added a reference of one of the review articles on this (reference number 7). We however, did not add the whole technology appraisal from early 2000s in detail in the manuscript as most of these technologies are obsolete. Also we wanted our Introduction Section to focus in the currently commercially available point-of-care (POC) or near-POC CD4 assays in the market (line 110-113).
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Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening

PONE-D-19-30572R1

Dear Dr. Ndlovu,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Bharat S. Parekh, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for addressing reviewers\' comments. Manuscript is now acceptable for publication.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1) Again, on line 242, the authors state, \"In restricting the analysis to samples with CD4\<100cells/mm3 cut-off in the reference test, the sensitivity of the Visitect CD4 LFA (at its standard 200cells/mm3 threshold) in detecting samples with CD4\<100cells/mm3 was 98.1% \[IQR: 93.5 -- 99.8\] and specificity was 68.0% \[IQR: 64.1 -- 71.7\]\". If you truly restricted the analysis to samples with CD4 \< 100 cells/mm3, the specificity would be 0% as there would be 0 samples \> 100 cells/mm3 for the reference assay. I suspect the authors analyzed all samples (less than and greater than the cut-offs), however varied the reference test cut-offs. If this is true, changing this sentence to say, \"In analyzing samples at varying reference test cut-offs, the sensitivity of the Visitect CD4 LFA\...\" would render it accurate.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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PONE-D-19-30572R1

Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening

Dear Dr. Ndlovu:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Bharat S. Parekh

Academic Editor

PLOS ONE
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